Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Uveal Melanoma 1Melanoma 1Lymphoma, Mantle-Cell 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 165Cyclophosphamide 163fludarabine phosphate 95Peripheral Blood Stem Cell Transplantation 88Filgrastim 72Etoposide 65Mycophenolic Acid 63Whole-Body Irradiation 62Cytarabine 59Cyclosporine 53Melphalan 52Tacrolimus 47Busulfan 43Radiotherapy 42Lenalidomide 42Bortezomib 40ibrutinib 39fludarabine 39Methotrexate 38Antilymphocyte Serum 38Carmustine 37Bendamustine Hydrochloride 35Vincristine 33Doxorubicin 32Dexamethasone 32Granulocyte Colony-Stimulating Factor 29Prednisone 26Cord Blood Stem Cell Transplantation 25venetoclax 22obinutuzumab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Mantle-Cell × sotrastaurin × Clear all
NCT02285244 2017-04-05

Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation

Ohio State University Comprehensive Cancer Center

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡